Cognition Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
The meeting was held virtually, confirming quorum and addressing two proposals: election of directors and ratification of the auditor. Both proposals passed by the required vote, with final results to be filed in an 8-K. A Q&A session followed the formal meeting.
-
The presentation highlighted a promising oral therapy for psychosis in Lewy body dementia, showing strong efficacy and safety in phase II trials, with a registrational program underway. Alzheimer's data also showed significant slowing of disease progression, and further results are expected next year.
-
Preparations are underway for Phase III trials of zervimesine, focusing on DLB psychosis after strong Phase II results and regulatory feedback. The Alzheimer's START trial is fully enrolled, with results expected in Q3 2027, and both programs maintain a favorable safety profile.
Fiscal Year 2025
-
Prioritizing zervimesine for DLB psychosis after strong phase II results, with registrational trial planning underway and positive regulatory feedback. Cash runway extends through Q2 2027, and Alzheimer's program continues with START trial results expected in 2027.
-
CT1812 demonstrated broad efficacy in DLB and Alzheimer's, especially in patients with low p-tau217, and is advancing to Phase 3 with regulatory support for composite endpoints and a six-month trial. The oral drug is well tolerated and may expand to other neurodegenerative indications.
-
Lead drug zervimesine demonstrated strong safety and efficacy in both Alzheimer's and Lewy body dementia, with significant slowing of disease progression and improved caregiver outcomes. Phase III planning is underway, with active partner discussions and a focus on securing funding.
Fiscal Year 2024
-
Zervimesine showed strong efficacy in Alzheimer's and DLB, with all resources now focused on these programs. Cash and grants support operations into late 2025, while partnership and funding discussions continue. Key FDA meetings and milestones are expected this year.
-
The phase II SHIMMER trial in DLB showed CT-1812 slowed disease progression by 50–90% across behavioral, cognitive, functional, and motor domains, with a strong safety profile at 100 mg. These results support advancing CT-1812 to larger studies to address a major unmet need.
-
Recent phase II data showed the oral therapy slowed cognitive decline in Alzheimer's patients, with especially strong results in those with low tau levels. The drug demonstrated a favorable safety profile, can be used with existing treatments, and is advancing toward phase III trials.
-
SHINE phase 2 results show CT1812 significantly slowed cognitive decline in mild to moderate Alzheimer's, with patients having low baseline p-tau217 experiencing no cognitive loss over six months. The drug was well tolerated, and findings support advancing to phase 3 trials targeting this biomarker-defined subgroup.
-
Presentations highlighted CT-1812's promising results in slowing cognitive decline in Alzheimer's, with strong safety and potential for first oral treatments in DLB and dry AMD. Multiple trials are ongoing, supported by robust funding and strategic partnerships.
-
CT-1812 showed a 39% slowing of cognitive decline in Alzheimer's over six months, with strong safety at 100 mg and promising biomarker results. Cash runway extends into Q2 2025, with multiple Phase 2 trials ongoing and key data readouts expected by year-end.